Literature DB >> 20500117

Nosocomial imipenem-resistant Acinetobacter baumannii infections: epidemiology and risk factors.

Murat Dizbay1, Ozlem Guzel Tunccan, Busra Ergut Sezer, Kenan Hizel.   

Abstract

The incidence, clinical characteristics, risk factors, antimicrobial susceptibility, and outcomes of nosocomial imipenem-resistant A. baumannii (IRAB) infections during a 5-y period (2003-2007) were retrospectively analyzed. A total of 720 patients with 925 episodes of A. baumannii infection were included in the study. A. baumannii infections were seen mostly in intensive care units. The incidence was 6.2 per 1000 admissions. The most common infections were pneumonias and bloodstream infections. Imipenem resistance among Acinetobacter strains increased significantly each y of the study (from 43.3% to 72.9%). Mortality was related to the presence of imipenem resistance, stay in intensive care unit, female gender, old age, and pneumonia. Haemodialysis, malignancy, and mechanical ventilation were significant risk factors for IRAB infections. Imipenem resistance was higher in strains isolated from patients with pneumonia. IRAB strains showed higher resistance rates to other antibiotics than imipenem-susceptible strains. The most active antimicrobial agents against A. baumannii were cefoperazone-sulbactam and netilmicin. The incidence of A. baumannii infections and imipenem resistance increased during the study period. IRAB infections should be considered in patients on mechanical ventilation and haemodialysis and in patients with malignancies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20500117     DOI: 10.3109/00365548.2010.489568

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  22 in total

1.  Mathematical model to quantify the effects of risk factors on carbapenem-resistant Acinetobacter baumannii.

Authors:  Michelle W Tan; David C Lye; Tat-Ming Ng; Michael Nikolaou; Vincent H Tam
Journal:  Antimicrob Agents Chemother       Date:  2014-06-23       Impact factor: 5.191

2.  Combating antimicrobial resistance: policy recommendations to save lives.

Authors:  Brad Spellberg; Martin Blaser; Robert J Guidos; Helen W Boucher; John S Bradley; Barry I Eisenstein; Dale Gerding; Ruth Lynfield; L Barth Reller; John Rex; David Schwartz; Edward Septimus; Fred C Tenover; David N Gilbert
Journal:  Clin Infect Dis       Date:  2011-05       Impact factor: 9.079

3.  Molecular epidemiology and characterization of multiple drug-resistant (MDR) clinical isolates of Acinetobacter baumannii.

Authors:  Sherief El-Shazly; Ali Dashti; Leila Vali; Michael Bolaris; Ashraf S Ibrahim
Journal:  Int J Infect Dis       Date:  2015-10-27       Impact factor: 3.623

4.  Emergence of Carbapenem Resistant Non-Fermenting Gram-Negative Bacilli Isolated in an ICU of a Tertiary Care Hospital.

Authors:  Sonika Agarwal; Barnali Kakati; Sushant Khanduri; Shalini Gupta
Journal:  J Clin Diagn Res       Date:  2017-01-01

5.  Identification of Ata, a multifunctional trimeric autotransporter of Acinetobacter baumannii.

Authors:  Leticia V Bentancor; Ana Camacho-Peiro; Cagla Bozkurt-Guzel; Gerald B Pier; Tomás Maira-Litrán
Journal:  J Bacteriol       Date:  2012-05-18       Impact factor: 3.490

6.  Acinetobacter baumannii rOmpA vaccine dose alters immune polarization and immunodominant epitopes.

Authors:  Lin Lin; Brandon Tan; Paul Pantapalangkoor; Tiffany Ho; Andrea M Hujer; Magdalena A Taracila; Robert A Bonomo; Brad Spellberg
Journal:  Vaccine       Date:  2012-11-12       Impact factor: 3.641

7.  Assessing the burden of Acinetobacter baumannii in Maryland: a statewide cross-sectional period prevalence survey.

Authors:  Kerri A Thom; Lisa L Maragakis; Katie Richards; J Kristie Johnson; Brenda Roup; Patricia Lawson; Anthony D Harris; Elizabeth P Fuss; Margaret A Pass; David Blythe; Eli N Perencevich; Lucy Wilson
Journal:  Infect Control Hosp Epidemiol       Date:  2012-07-23       Impact factor: 3.254

8.  The deadly impact of extreme drug resistance in Acinetobacter baumannii.

Authors:  Brad Spellberg; Robert A Bonomo
Journal:  Crit Care Med       Date:  2014-05       Impact factor: 7.598

9.  Identifying Risk Factors for Healthcare-Associated Infections Caused by Carbapenem-Resistant Acinetobacter baumannii in a Neonatal Intensive Care Unit.

Authors:  Amira M Sultan; Wael A Seliem
Journal:  Sultan Qaboos Univ Med J       Date:  2018-04-04

10.  Inhibition of LpxC protects mice from resistant Acinetobacter baumannii by modulating inflammation and enhancing phagocytosis.

Authors:  Lin Lin; Brandon Tan; Paul Pantapalangkoor; Tiffany Ho; Beverlie Baquir; Andrew Tomaras; Justin I Montgomery; Usa Reilly; Elsa G Barbacci; Kristine Hujer; Robert A Bonomo; Lucia Fernandez; Robert E W Hancock; Mark D Adams; Samuel W French; Virgil S Buslon; Brad Spellberg
Journal:  MBio       Date:  2012-10-02       Impact factor: 7.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.